These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [The validity of chemotherapy in the treatment of endometrial cancer]. Fehr MK; Streich MS Gynakol Geburtshilfliche Rundsch; 2006; 46(1-2):34-8. PubMed ID: 16452818 [TBL] [Abstract][Full Text] [Related]
23. Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway. Lee PS; Secord AA Cancer Treat Rev; 2014 May; 40(4):507-12. PubMed ID: 24332498 [TBL] [Abstract][Full Text] [Related]
24. A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258). Infante JR; Ramanathan RK; George D; Tan E; Quinlan M; Liu A; Scott JW; Sharma S Cancer Chemother Pharmacol; 2015 Apr; 75(4):729-37. PubMed ID: 25648347 [TBL] [Abstract][Full Text] [Related]
25. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683 [TBL] [Abstract][Full Text] [Related]
26. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer. Lim SM; Chung WY; Nam KH; Kang SW; Lim JY; Kim HG; Shin SH; Sun JM; Kim SG; Kim JH; Kang CW; Kim HR; Cho BC Eur J Cancer; 2015 Aug; 51(12):1588-95. PubMed ID: 26070683 [TBL] [Abstract][Full Text] [Related]
27. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer. Clin Cancer Res; ; . PubMed ID: 24691021 [TBL] [Abstract][Full Text] [Related]